Mesoblast to file biologics license application for ryoncil® fda approval next week

New york, july 01, 2024 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its biologics license application (bla) for approval of ryoncil® (remestemcel-l) in the treatment of children with steroid-refractory acute graft versus host disease (sr-agvhd) with the u.s. food and drug administration (fda) next week.
MESO Ratings Summary
MESO Quant Ranking